Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Apr 1;47(4):504-509.
doi: 10.1097/DSS.0000000000002846.

A Multicenter Study to Evaluate Subject Satisfaction With Two Treatments of AbobotulinumtoxinA a Year in the Glabellar Lines

Joel Schlessinger  1 , Joel L Cohen  2 , Ava Shamban  1   2   3   4   5   6   7 , Carolyn Jacob  3 , Kian Karimi  4 , Corey Maas  5 , Vanessa Lane  6 , Sarah Coquis-Knezek  7 , Matthew Meckfessel  7
Affiliations
Clinical Trial

A Multicenter Study to Evaluate Subject Satisfaction With Two Treatments of AbobotulinumtoxinA a Year in the Glabellar Lines

Joel Schlessinger et al. Dermatol Surg. .

Abstract

Background: Real-world re-treatment intervals for botulinum toxins vary, but most subjects receive treatment less frequently than the manufacturer-recommended minimum intervals. In subjects receiving treatment with AbobotulinumtoxinA (ABO) less frequently, high levels of satisfaction and psychosocial improvements in well-being, self-confidence, and quality of life are observed.

Objective: To evaluate subject satisfaction with a twice yearly re-treatment schedule.

Methods and materials: This open-label, multicenter, interventional study evaluated subject satisfaction following injections of ABO 50 U in the glabellar lines at baseline and 6 months. The primary end point was subject satisfaction at 12 months. Secondary endpoints included subject satisfaction, FACE-Q scales, and glabellar line severity scale (GLSS).

Results: Ninety-five percent of the 120 subjects were "highly satisfied" or "satisfied" with their treatment outcomes at 12 months. FACE-Q total scores suggested that subjects were less bothered by glabellar lines and felt better about their facial appearance with each treatment versus baseline. Approximately half of subjects had ≥1-grade improvement from baseline in GLSS at 12 months. Median onset of effect was 2 days.

Conclusion: The majority of subjects (95%) were satisfied with ABO treatment every 6 months; results were supported by high subject satisfaction, long duration, rapid onset, natural-looking results, and overall psychological wellness and safety.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Subject satisfaction after 2 treatments a year (+mITT (N = 113), subjects assessed (n = 110). Numbers may exceed 100% due to rounding).
Figure 2.
Figure 2.
Subject results at maximum frown at 6 months posttreatment. All patients have given permission for reproduction of photographs.
Figure 3.
Figure 3.
Subject views of treatment impact by assessment time point.
Figure 4.
Figure 4.
Improvement from baseline in GLSS (≥1-grade). GLSS, glabellar line severity scores. McNemar's test, comparing Month 3 to Month 9; Month 6 to Month 12. *p = .2393; †p = .0348; ‡p < .0001; ¶p = .0053.
See this image and copyright information in PMC

References

    1. Monheit GD, Baumann L, Maas C, Rand R, et al. . Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment for moderate to severe glabellar lines. Dermatol Surg 2020;46:61–9. - PubMed
    1. Dysport US Prescribing Information. Fort Worth, TX: Galderma Laboratories, LP; 2019.
    1. Azzalure/Dysport Summary of Product Characteristics. Wrexham, United Kingdom: Ipsen Biopharm Limited; 2019.
    1. Ascher B, Zakine B, Kestemont P, Baspeyras M, et al. . A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 2004;51:223–33. - PubMed
    1. Rzany B, Ascher B, Fratila A, Monheit GD, et al. . Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch Dermatol 2006;142:320–6. - PubMed

Publication types

Substances